GlaxoSmithKline plc 2.9% Potential Decrease Indicated by UBS

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

GlaxoSmithKline plc with EPIC/TICKER (LON:GSK) had its stock rating noted as ‘Unchanged’ with the recommendation being set at ‘NEUTRAL’ today by analysts at UBS. GlaxoSmithKline plc are listed in the Health Care sector within UK Main Market. UBS have set a target price of 1610 GBX on its stock. This would imply the analyst believes there is a potential downside of -2.9% from the opening price of 1658.2 GBX. Over the last 30 and 90 trading days the company share price has increased 65.2 points and increased 98.2 points respectively. The 1 year high for the share price is 1672.2 GBX while the year low share price is currently 1408.8 GBX.

GlaxoSmithKline plc has a 50 day moving average of 1,597.79 GBX and a 200 Day Moving Average share price is recorded at 1,556.74. There are currently 4,988,152,200 shares in issue with the average daily volume traded being 8,288,573. Market capitalisation for LON:GSK is £82,414,248,212 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    GSK's Arexvy vaccine receives approval in Japan to protect adults aged 50-59 at increased risk from severe RSV infection, expanding its coverage.
    GSK Plc reports Q3 2024 results with strong growth in Specialty Medicines offsetting lower Vaccine sales. Core earnings rose by 5%, despite Zantac charges.
    GSK's new antibiotic gepotidacin earns FDA's Priority Review, marking potential first new uUTI oral treatment in 20 years, with decision due March 2025.

      Search

      Search